

***Amendments to the Claims***

The listing of claims will replace all prior versions, and listings of claims in the application.

15. (Previously presented) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2.

16-21. (Canceled)

22. (Previously presented) A composition comprising the polypeptide of claim 15 and a pharmaceutically acceptable carrier.

23-35. (Canceled)

36. (Previously presented) An *ex vivo* method for treating an individual comprising:

(a) incubating cytotoxic T lymphocyte (CTL) precursor cells obtained from the individual with antigen presenting cells and the polypeptide of claim 15;

(b) allowing said precursor cells to mature and expand to effector CTLs;  
and

(c) readministering said effector CTLs to the individual.

37-39. (Canceled)